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Abstract
Synucleinopathies [Parkinson’s disease with or without dementia, dementia with Lewy bodies and multiple system
atrophy] are neurodegenerative diseases that are defined by the presence of filamentous α-synuclein inclusions. We
investigated the ability of luminescent conjugated oligothiophenes to stain the inclusions of Parkinson’s disease
and multiple system atrophy. They stained the Lewy pathology of Parkinson’s disease and the glial cytoplasmic
inclusions of multiple system atrophy. Spectral analysis of HS-68-stained inclusions showed a red shift in multiple
system atrophy, but the difference with Parkinson’s disease was not significant. However, when inclusions were
double-labelled for HS-68 and an antibody specific for α-synuclein phosphorylated at S129, they could be
distinguished based on colour shifts with blue designated for Parkinson’s disease and red for multiple system
atrophy. The inclusions of Parkinson’s disease and multiple system atrophy could also be distinguished using
fluorescence lifetime imaging. These findings are consistent with the presence of distinct conformers of assembled
α-synuclein in Parkinson’s disease and multiple system atrophy.
Keywords: α-Synuclein, Luminescent conjugated oligothiophene, Multiple system atrophy, Neurodegeneration,
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Introduction
Accumulation of α-synuclein (α-syn) assemblies is the
pathological hallmark of a group of neurodegenerative dis-
eases called synucleinopathies [1]. Parkinson’s disease (PD)
is the most common synucleinopathy and the second most
common neurodegenerative disease, after Alzheimer’s dis-
ease (AD). Diagnosis requires bradykinesia, in conjunction
with at least one of the following signs: rigidity, tremor and
postural instability. However, post mortem examination of
the brain is required to firmly establish diagnosis [2]. Neu-
ropathologically, PD is characterised by dopaminergic nerve
cell loss in the pars compacta of the substantia nigra and
the presence of filamentous α-syn assemblies in the form of
Lewy bodies (LBs) and Lewy neurites (LNs). The α-syn of
LBs and LNs [3] is post-translationally modified, with phos-
phorylation of S129 (pS129) being the most prominent
modification [4, 5]. While only approximately 4% of α-syn
is phosphorylated at S129 in normal brain, more than 90%
of assembled α-syn carries this modification [5]. Therefore,
antibodies directed against pS129 are often used to identify
α-syn deposits in PD and other synucleinopathies.
Assemblies of α-syn are also characteristic of Lewy body
dementia (LBD) and multiple system atrophy (MSA) [6–8].
LBD encompasses cases of dementia with Lewy bodies
(DLB) and Parkinson’s disease dementia (PDD) [1, 9]. MSA
includes cases of olivopontocerebellar atrophy, striatonigral
degeneration and mixed MSA as determined by the pattern
of neurodegeneration on examination of post mortem brain
tissue [10, 11]. LBD presents predominantly as a progres-
sive dementia with varying degrees of motor involvement,
whereas MSA is characterized by a combination of parkin-
sonian, cerebellar and autonomic symptoms. In MSA, α-
syn aggregates are present in both nerve cells and glial cells,
chiefly oligodendrocytes, where they form glial cytoplasmic
inclusions (GCIs) [6–8, 11]. α-Syn filaments isolated from
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the brains of MSA patients can have different morphologies
from those extracted from the brains of patients with PD
and DLB [6, 12–15]. Moreover, LBs and GCIs demonstrate
different abilities to seed α-syn aggregation in cell culture
and in mouse models [15–19]. These results have led to the
hypothesis that aggregated α-syn has different conformations
in PD and MSA brains, a phenomenon that has previously
been established for assembled tau in Alzheimer’s and Pick’s
diseases by electron cryo-microscopy [20, 21].
Luminescent conjugated oligothiophenes (LCOs) are
fluorescent ligands that detect protein aggregates in human
diseases and models thereof [22]. Solid-state nuclear mag-
netic resonance has shown that LCOs bind in grooves along
the filament axis of HET-s aggregates, where they interact
with charged amino acids [23]. LCOs detect a larger
spectrum of aggregates than amyloid ligands, such as Congo
red and thioflavins [24, 25]. The colour of light emitted from
a given LCO is determined by the conformation of its flex-
ible thiophene backbone, which in turn depends on the con-
formations of the assemblies it binds to. Thus, distinct
conformers of assembled proteins can be separated based
on the colour of the LCO, and this has provided new infor-
mation about prion and Aβ strains [26, 27].
Here we show that LCOs can be used to detect α-syn
assemblies in brain from patients with PD and MSA. We
also show that, in combination with labelling of pS129
α-syn, they provide evidence for the existence of distinct
conformers of assembled α-syn.
Materials and methods
LCO staining
Frozen brain tissues from neuropathologically confirmed
cases of PD and MSA, as well as healthy controls, were
obtained from the Queen Square Brain Bank and the
Dementia Laboratory at the Department of Pathology
and Laboratory Medicine, Indiana University School of
Medicine. Brain regions were substantia nigra and/or
cingulate gyrus for PD, cerebellum for MSA, and cere-
bellum and midbrain at the level of substantia nigra for
healthy controls. See Table 1 for additional information.
The synthesis of HS-68 has been described [28]. Frozen
brain sections (10 μm) were fixed in 96% ethanol for 10
min, rehydrated and incubated in phosphate-buffered sa-
line (PBS) for 10 min. HS-68 (3 μM in PBS) was added
for 30 min at room temperature. The sections were then
washed in PBS and mounted (Dako). The mounting
medium was allowed to solidify for approximately 20 h
before the samples were analysed. Sections were also
stained with LCOs p-FTAA and h-FTAA. Syntheses of
p-FTAA and h-FTAA have been described [24, 29].
Immunohistochemistry
Frozen brain sections (10 μm) were fixed in acetone at −
20 °C for 5 min, allowed to dry for 30min and rehydrated
in PBS for 1min. They were then incubated in PBS with
5% normal goat serum (blocking buffer) for 30min at
room temperature. A rabbit monoclonal antibody specific
for pS129 α-syn (ab51253, Abcam) was used at 1:1000 in
blocking buffer. After 2 h at room temperature, the sec-
tions were washed with PBS for 3 × 5 min and signal visu-
alized with a goat anti-rabbit antibody conjugated to
Alexa 488 fluorophore (Thermo Fisher Scientific) diluted
1:400 in blocking buffer. After 1 h at room temperature,
the sections were washed with PBS for 3 × 5 min and
mounted. Fluorescence images were collected using an
inverted Zeiss LSM 780 confocal microscope.
Double-labelling
Brain sections were stained with anti-pS129 α-syn as de-
scribed above, with the exception that goat anti-rabbit
secondary antibody conjugated with Alexa 647 (Thermo
Fisher Scientific) was used (1:200 in blocking buffer) to
avoid interference with LCO emission. PD sections were
also stained with anti-α-syn antibody (Syn303, 1:1000,
Biolegend), anti-phosphorylated tau antibody (AT100, 1:
250, Thermo Fisher Scientific), anti-p62 antibody (1:100,
BD Bioscience) and anti-TDP-43 antibody (1:500,
Table 1 Description of cases
Case no Diagnosis Brain region Age/Sex
1 MSA Cbl 75/F
2 MSA Cbl 82/M
3 MSA Cbl 68/F
4 MSA Cbl 69/M
5 MSA Cbl 65/F
6 MSA Cbl 71/F
7 MSA Cbl 83/F
8 MSA Cbl 52/M
9 PD Sn/Cg 74/F
10 PD Sn/Cg 92/M
11 PD Sn/Cg 64/M
12 PD Sn/Cg 83/M
13 PD Sn 74/M
14 PD Sn 79/M
15 PD Sn 86/F
16 PD Sn 75/M
17 PD Cg 92/F
18 Control Cbl 82/F
19 Control Cbl 56/F
20 Control Cbl 80/M
21 Control Cbl/Mb-Sn 69/M
22 Control Cbl/Mb-Sn 74/M
Cbl cerebellum, Cg cingulate gyrus, Mb midbrain, MSA multiple system
atrophy, PD Parkinson’s disease, Sn substantia nigra
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Proteintech Group Inc.). After washing 3 × 5 min in
PBS, they were incubated with 3 μM HS-68 for 30 min at
room temperature. They were then washed with PBS
and mounted with Dako mounting medium. Fluores-
cence images and emission spectra were collected using
an inverted Zeiss LSM 780 confocal microscope.
Spectral analysis
Spectral analysis was performed on frozen brain sections
fixed with ethanol and stained with HS-68, and on sec-
tions fixed with acetone and double-labelled with HS-68
and anti-pS129 α-syn antibody. Emission spectra were
collected from HS-68-labelled structures using an excita-
tion wavelength of 405 nm. For pS129-positive α-syn ag-
gregates labelled with HS-68, an excitation wavelength
of 458 nm was used. Spectral analysis was performed on
an inverted Zeiss LSM 780 confocal microscope. In
ethanol-fixed sections, the HS-68 spectrum from 1 to 10
regions of interest per aggregate was collected from at
least 15 aggregates per sample. However, for samples 11,
9* and 11*, the number of analysed aggregates was less.
In the HS-68 and pS129 co-labelling spectral experi-
ment, 3 PD and 3 MSA cases were included. The num-
ber of analysed double labelled aggregates was 29 or
more, each containing 2–14 regions of interest.
Fluorescence lifetime imaging
Sections were stained with pS129 α-syn antibody and h-
FTAA as described above, and fluorescence lifetime im-
aging of stained tissue sections was acquired on an
inverted Zeiss LSM 780 confocal microscope equipped
with a 32 channel QUASAR GaAsP spectral array de-
tector. Emitted photons were routed through the direct
coupling confocal port of the Zeiss LSM 780 scanning
unit and detected by a Becker & Hickl HPM-100-40 hy-
brid photomultiplier tube (Becker & Hickl GmbH). Data
were recorded by a Simple-Tau 152 system (SPC-150
TCSPC FLIM module) with the instrument recording
software SPCM version 9.42 in the FIFO image mode
using 256 time-channels. A Plan-Apochromat 40×/1.3
Oil DIC objective lens was used, and the pinhole set to
20.2 μm. For excitation at 490 nm, a pulsed tunable In
Tune laser with a repetition rate of 40MHz was used.
Analysis used SPCImage version 3.9.4; 17–44 α-syn ag-
gregates from 3 PD and 3 MSA cases were included.
Statistics
Each spectrum represents the mean emission for a num-
ber of regions of interest collected from either a single ag-
gregate or a group of aggregates. For HS-68, the plots
show the ratio of fluorescence intensity for each region of
interest at emission wavelengths of 485 or 486 and 573
nm (485/573R, 486/573R). The standard deviation (S.D.)
for each sample is included in the ratio plot graph. To
determine if there was a significant difference in LCO
emission between α-syn aggregates in PD and MSA, a
Mann-Whitney test (GraphPad Prism 6) was performed.
Results
LCO staining
Brain sections from patients with MSA and PD were
stained with HS-68 (Fig. 1a). Staining was compared
with that of an antibody specific for pS129 α-syn. In
MSA, the pS129 antibody labelled GCIs, which varied in
size and appearance, being sickle-, flame- or ghost-
shaped, and HS-68 displayed a similar staining pattern
(Fig. 1b). In PD, pS129-positive LBs appeared as cyto-
plasmic spheres and, occasionally, tangle-like assemblies.
LNs and neuropil threads were also seen. All α-syn de-
posits identified by the pS129 antibody were stained by
HS-68. Staining of LBs with HS-68 was more
homogenous than with the pS129 antibody which, in
most cases, only labelled the LB periphery (Fig. 1b). In
PD, HS-68 staining was weaker for a small number of
aggregates than for the majority of inclusions.
Spectral analysis of inclusions stained by HS-68
Emission spectra of HS-68 varied within and between
cases of MSA and PD (Fig. 2). They were further analysed
by calculating the ratios of fluorescence intensity at wave-
lengths with the most pronounced variation. Most cases
of MSA displayed a lower mean than PD cases, indicating
a red shift of emission (Fig. 2a, b), but the difference was
not statistically significant (Fig. 2b). However, in PD sam-
ples stained with HS-68, emission spectra divided aggre-
gates into two groups: a red-shifted cluster that
overlapped with MSA and a blue-shifted cluster that did
not overlap (Fig. 2a). Blue-shifted aggregates included LBs,
whereas red-shifted aggregates were smaller (Fig. 3). For
some PD cases, spectral analysis was performed on protein
inclusions from both substantia nigra and cingulate gyrus
(Table 1). Although the means were not identical, the
spectral trends were similar (Fig. 2a). However, in cingu-
late gyrus, the cluster of aggregates that did not spectrally
overlap with MSA showed a less pronounced blue-shift
compared with the corresponding cluster in substantia
nigra. We also used LCOs p-FTAA and h-FTAA for spec-
tral analysis [24, 29]. Similar to HS-68, they bound to in-
clusions identified by the pS129 α-syn antibody. However,
HS-68 was better at identifying shifts in colour between
MSA and PD.
Double-labelling (HS-68 and pS129 α-syn antibody)
In MSA cerebellar white matter, co-localisation be-
tween HS-68 and the pS129 α-syn antibody was ob-
served (Fig. 3a). The labelling intensity of the
antibody varied, with some GCIs showing a weaker
signal. In PD, two types of aggregate were present: i)
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HS-68-positive, pS129-positive; ii) HS-68-positive,
pS129-negative (Fig. 3b, c). Fluorescence intensity var-
ied in the first group, with a small number of aggre-
gates only displaying weak HS-68 staining (Fig. 3d).
Only the pS129-positive inclusions were blue-shifted
(Fig. 3e). The pS129-negative species, which were
smaller than LBs, represented the red-shifted cluster
of aggregates (Fig. 2a). Labelling with Syn303, AT100,
anti-p62 and anti-TDP-43 antibodies showed no co-
localisation with HS-68 in these structures. It therefore
remains to be determined what the constituents of the red-
shifted HS-68-positive and pS129-negative aggregates in PD
are. In general, when performing double-labelling, the HS-68
emission spectrum was red-shifted, with the shoulder at 573
nm being more pronounced and that at 485 nm almost
abolished (Fig. 3e), compared to when only HS-68 was used
(Fig. 2a). This was probably because another fixative (acetone
instead of ethanol) and a different excitation wavelength were
used. No co-labelling of HS-68 and pS129 α-syn antibody
could be seen in the control cases.
Spectral analysis of double-labelled aggregates
A second spectral analysis was performed that included
only aggregates labelled by both HS-68 and the pS129 α-
syn antibody. HS-68 emission graphs gave a similar max-
imum at 529 nm (PD) and/or 538 nm (MSA) (Fig. 4a);
however, the overall contour of the spectra revealed a
shift in colour. In PD sections, there was a distinct emis-
sion shoulder at 485 nm, which was not present in MSA
(Fig. 4a). Instead, the dominating shoulder in MSA was
at 573 nm. These differences show that pS129 α-syn as-
semblies in PD were blue-shifted relative to MSA. To as-
sess the results in more detail, and to visualize the
spectral distribution of each sample, the ratios of fluor-
escence intensity at 485 nm and 573 nm (485/573R) were
calculated. PD samples showed a higher mean than
MSA cases, confirming the blue-shift in emission (Fig.
4b). Spectral differences were significant (Fig. 4c) and
showed that HS-68 can be used to separate the α-syn ag-
gregates of PD and MSA. The shift in colour indicates
that HS-68 binds differently to α-syn assemblies in PD
Fig. 1 HS-68-positive inclusions in multiple system atrophy (MSA) and Parkinson’s disease (PD). a Structure of the luminescent conjugated
oligothiophene HS-68. b MSA and PD brain sections from cases 8 (cerebellum) and 15 (substantia nigra), respectively, stained with HS-68 and
labelled using the pS129 α-syn antibody. HS-68 stained glial cytoplasmic inclusions in MSA (arrowheads), as well as Lewy bodies and Lewy
neurites in PD (arrowheads). Red/orange structures represent autofluorescent lipofuscin. Scale bars, 20 μm.
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and MSA, suggesting that they are characterised by dif-
ferent assembled α-syn conformers.
Fluorescence lifetime imaging of h-FTAA-stained, pS129-
labelled α-syn aggregates
Measuring the decay of light emitted from a bound LCO
shows how it binds, since the fluorescence decay of a
fluorophore is sensitive to its conformation and the sur-
rounding chemical environment [30]. Fluorescence life-
time imaging (FLIM) microscopy using h-FTAA (Fig. 5a)
has previously revealed polymorphisms of prion aggre-
gates and Aβ plaques [31, 32]. We therefore investigated
the fluorescence lifetime of h-FTAA binding to pS129-
positive aggregates in PD and MSA. h-FTAA showed a
fluorescence decay of 300–700 ps in PD and of 250–600
ps in MSA (Fig. 5). Thus, a distinct distribution of fluores-
cence decay was observed, indicating that h-FTAA binds
in different ways to the binding pockets of PD and MSA
aggregates. No co-labelling of h-FTAA and pS129 α-syn
antibody could be seen in the control cases.
Discussion
LCOs have been used to study protein aggregates in hu-
man diseases and experimental models thereof [22].
Here we show that HS-68 can detect α-syn assemblies in
brain sections from patients affected by synucleinopathy.
The ligand showed strong emission when binding to
GCIs in MSA and various types of α-syn inclusions in
PD, and gave similar staining to that of an antibody spe-
cific for pS129 α-syn. However, when binding to LBs,
the LCO displayed more homogenous staining than the
antibody. Most brainstem LBs consist of a dense core
surrounded by a corona of radiating filaments [33]. HS-
68 stained both core and corona, whereas the antibody
labelled mostly the corona. The smaller size of HS-68
may have allowed better penetration. HS-68 exhibited a
greater variation in fluorescence intensity in PD than in
MSA. One explanation may be a greater diversity of
aggregates. Two types of LBs have been described
previously, with core and corona being more typical
of brainstem than cortical LBs [34]. Different shapes
of α-syn assemblies are also seen in neuronal
processes such as thread-like LNs and spheroid struc-
tures. Alternatively, HS-68 may bind to the weakly
fluorescent aggregates in a more quenched manner.
Like thioflavin T [35, 36], HS-68 may have to be ster-
ically locked in the binding pocket to become highly
fluorescent.
Fig. 2 Spectral analysis of HS-68-positive inclusions in multiple system atrophy (MSA) and Parkinson’s disease (PD). a Plot of the ratio of emission
intensities at wavelengths of 486 and 573 nm for HS-68 following binding to inclusions in MSA (coral circles) and PD (cyan squares). Cerebellum
was used for MSA; substantia nigra (filled squares) and cingulate gyrus (open squares) for PD. Each dot corresponds to a region of interest. The 8
cases of MSA (1–8) and 9 cases of PD (9–17) are listed in Table 1. Asterisk indicates cases for which both substantia nigra and cingulate gyrus
were used. Insert: Mean HS-68 emission spectra when binding to inclusions in brain tissues from MSA (coral) and PD (cyan). Each spectrum
represents one MSA (cerebellum) or one PD (substantia nigra and/or cingulate gyrus) case. Dashed lines indicate the wavelengths that were used
for calculating the ratio of emission intensity depicted in the plots. b Merging of the ratio values for all MSA (coral circles) and PD (cyan squares)
cases shown in a. The results are expressed as means ± S.D.; ns, not significant.
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Spectral properties of LCOs are conformation-dependent.
Structural analyses, as well as seeding experiments in cells
and animals, have suggested that α-syn aggregates may show
conformational variation [6, 12–19]. Spectral analysis of HS-
68 showed a red-shift for MSA aggregates, but the difference
with PD was not significant. However, when HS-68 and
pS129 α-syn antibody double-labelled aggregates were
analysed, the α-syn deposits of PD and MSA were distin-
guishable, because of their blue and red colours. Since the
emission profiles of LCOs are dependent on conformation
[22], it follows that α-syn assemblies in PD and MSA are con-
formationally distinct.
Differences in the cellular environment may underlie
the formation of distinct α-syn conformers in PD and
Fig. 3 HS-68- and pS129 α-syn antibody-positive inclusions in multiple system atrophy (MSA) and Parkinson’s disease (PD). a Fluorescence image
of brain tissue section from MSA case 8 (cerebellum) stained with HS-68 and labelled with pS129 α-syn antibody. GCIs (arrowheads) showed
complete co-localization between HS-68 and pS129 antibody. b-d Section from PD case 15 (substantia nigra) stained with HS-68 and pS129 α-syn
antibody, showing aggregates positive for HS-68 and pS129 (arrowheads) (b); HS-68-positive, pS129-negative, aggregates (arrowhead) (c); weakly
HS-68-positive, pS129-positive, aggregates (arrowheads) (d). Channels for single staining are shown in white to enhance visualization. Blue/
turquoise structures represent autofluorescent lipofuscin, which is also visible in the channel for HS-68 fluorescence. e Mean HS-68 emission
spectra collected from HS-68-positive, pS129-positive (solid line) and HS-68-positive, pS129-negative (dashed line) aggregates indicated by
arrowheads in b and c, respectively. A representative experiment is shown. Similar results were obtained using 2 additional cases of each PD and
MSA. Scale bars, 20 μm
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MSA. Thus, it has been reported that oligodendrocytes,
but not neurons, can convert α-syn into a conformer that
is like that of GCIs [16]. Moreover, injection of PD and
MSA brain extracts into mice transgenic for A53T α-syn
showed that the silver staining properties of induced neur-
onal assemblies of α-syn were dependent on both
transgene expression and cellular environment [37]. The
largest shifts in the HS-68 emission spectrum for α-syn as-
semblies of PD and MSA were present at wavelengths of
486 nm and 573 nm, respectively. Previously, intensity
shifts were found in the same region when Aβ plaques
and tau inclusions in young and old transgenic mice were
Fig. 4 Spectral analysis of HS-68- and pS129 α-syn antibody-positive inclusions in multiple system atrophy (MSA) and Parkinson’s disease (PD). a
Mean emission spectra of HS-68 binding to pS129 α-syn positive deposits in MSA cases 6, 7 and 8 (coral, cerebellum) and PD cases 13, 15 and 16
(cyan, substantia nigra). b Plot of the ratio of emission intensity at wavelengths 485 and 573 nm for HS-68 when binding to inclusions in MSA
(coral circles) and PD (cyan squares) that were also labelled with pS129 α-syn antibody. c Merging of the ratio values for all MSA (coral circles)
and PD (cyan squares) cases shown in b. The results are expressed as means ± S.D. (n = 3) ****p < 0.0001
Fig. 5 Fluorescence lifetime imaging of h-FTAA- and pS129 α-syn antibody-positive inclusions in multiple system atrophy (MSA) and Parkinson’s
disease (PD). a Structure of the luminescent conjugated oligothiophene h-FTAA. b Fluorescence intensity (top) and fluorescence lifetime (bottom)
images of h-FTAA stained pS129 positive α-syn inclusions in MSA (case 6, cerebellum) and PD (case 13, substantia nigra) brains. The colour bar
represents lifetimes from 200 ps (orange)-900 ps (blue) and the images are colour coded according to lifetime. c Fluorescence lifetime
distributions of h-FTAA bound to pS129 positive α-syn deposits in MSA (coral line) and PD (cyan line); 17–44 inclusions from 3 cases of MSA (6, 7
and 8, cerebellum) and 3 cases of PD (13, 15 and 16, substantia nigra) were used. Scale bar, 20 μm
Klingstedt et al. Acta Neuropathologica Communications           (2019) 7:193 Page 7 of 9
compared [38]. Aβ and tau deposits showed a shift from
red to blue in HS-68 emission, as the mice were ageing.
Since spectral analysis showed that the α-syn assemblies
of PD were blue-shifted relative to those of MSA, it is pos-
sible that the inclusions of PD were more mature. Also, in
PD, the blue-shift was more pronounced for inclusions in
substantia nigra, which is a region targeted early in the
disease progression, compared with inclusions in later in-
volved cingulate gyrus [39]. It has been reported that α-
syn assemblies from PD brains are less detergent-soluble
than those from MSA brains [13]. Moreover, PD is diag-
nosed at a similar age as MSA, but it has in general a sig-
nificantly longer duration [10]. It remains to be seen if
LCOs can distinguish between the α-syn inclusions of
atypical cases of PD and MSA with similar durations.
To characterise PD aggregates stained by HS-68,
but not labelled with the pS129 α-syn antibody, add-
itional co-labelling was performed. However, the
identity of the component(s) of these inclusions could
not be identified. Further analysis, perhaps combining
laser capture microdissection and mass spectrometry
or the use of epitope-specific α-syn antibodies, will
be needed. An alternative explanation for the lack of
co-labelling could be that antibody and LCO com-
peted for the same binding sites, as described for
prions [27].
We also performed FLIM of h-FTAA and pS129
antibody-labelled α-syn deposits in brain tissue sections.
The lifetime of a fluorophore, i.e. the time it spends in
the excited state before returning to the ground state, is
dependent on its conformation and on how it interacts
with its environment [30]. One example is the difference
in fluorescence decay exhibited by h-FTAA when bind-
ing to distinct prion conformers [31]. FLIM analysis of
h-FTAA has also been used to distinguish Aβ morpho-
types associated with ApoE deficiency in APPPS1 mice
[32]. We now show that the fluorescence decay of h-
FTAA differed when binding to α-syn aggregates in PD
compared to MSA. Hence, similar to the spectral result,
FLIM demonstrated that LCOs can interact in different
ways with α-syn deposits in PD and MSA.
In conclusion, we show that LCOs can be used to de-
tect accumulations of α-syn in PD and MSA. Moreover,
by analysing LCO staining, we show that pS129 positive
α-syn aggregates in PD differ from those in MSA regard-
ing ligand stainability, emission profiles and fluorescence
lifetimes. It follows that distinct conformations of assem-
bled α-syn are present in the brains of patients with PD
and MSA. Structural analysis of α-syn filaments from
PD and MSA brains is required to prove the existence of
distinct conformers and identify their differences.
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